Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05581589 · ClinicalTrials.gov registry record · Phase 2
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
A Phase 2 study of Muscle-Invasive Bladder Carcinoma and Stage II Bladder Cancer AJCC v8, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05581589 is a Phase 2 study of Muscle-Invasive Bladder Carcinoma and Stage II Bladder Cancer AJCC v8 that is actively recruiting participants, run by University of Washington. The registered enrollment target is 18 participants, below the 124-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05581589, a Phase 2 study of Muscle-Invasive Bladder Carcinoma and Stage II Bladder Cancer AJCC v8, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer. Sacituzumab govitecan contains a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan before radical cystectomy may make the surgery more effective in patients with muscle invasive bladder cancer.
Conditions Studied
Interventions
- PROCEDURE Lymphadenectomy
- BIOLOGICAL Sacituzumab Govitecan
- PROCEDURE Radical Cystectomy
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05581589
The ClinicalTrials.gov registry entry for NCT05581589 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 124-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (85% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Muscle-Invasive Bladder Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Lymphadenectomy is the first listed.
NCT05581589 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT05581589 about?
NCT05581589 is a clinical study titled "Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer". This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer. Sacituzumab govitecan contains a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of t...
What is the current status of trial NCT05581589?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2023-06-15. Estimated completion is 2027-04-30.
What conditions does trial NCT05581589 study?
This clinical trial studies the following conditions: Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8.
What interventions are being tested in trial NCT05581589?
The interventions under investigation include: Lymphadenectomy (PROCEDURE), Sacituzumab Govitecan (BIOLOGICAL), Radical Cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT05581589?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05581589 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-Invasive Bladder Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
RECRUITING · Phase 2
-
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
RECRUITING · Phase 2
-
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
RECRUITING · Phase 2
-
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Muscle-Invasive Bladder Carcinoma
All registered trials for this condition
Stage II Bladder Cancer AJCC v8
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.